Biomarkers, particularly molecular biomarkers, are key indicators of biological processes in normal and diseased conditions. Recent research on their role in pathogenesis, coupled with the advancement of laboratory technology, has allowed for the objective measurement of biomarkers at a cellular level. This increase in research on molecular biomarkers has yielded more information for clinical investigators to properly assess disease diagnosis, prognosis, treatment, and management. Since 2003, the FDA has approved 139 tests for biomarkers.
Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma Differentiation by New miRNA Biomarker Panel
Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CC) are two highly aggressive malignant tumor types, associated with poor prognosis. Owing to their overlapping immunohistochemical profiles and morphological similarity, they are virtually indistinguishable histologically.
Squamous Cell Carcinoma Differentiation of Cervical Cancer using New miRNA Biomarker Panel
Cervical cancer is one of the most common malignant tumors of the female reproductive tract. It is the second most common cause of female cancer mortality. Cervical cancer is preventable and generally curable if detected early.
Glioma Prognostic Subtyping – Astrocytoma, Oligodendroglioma, Meningioma, and Glioblastoma using New miRNA Biomarker Panel
Malignant gliomas are extremely aggressive and lethal form of brain tumors. Despite considerable advances in surgery, radiotherapy and chemotherapy, the prognosis for patients with gliomas remains poor.
Biomarker Panel for Differentiation of Wild Type and Breast Cancer Susceptibility Gene (BRCA) Mutated Breast Cancer
Breast cancer represents a heterogeneous group of tumors characterized by a wide range of clinical, pathologic and molecular features. Genetic susceptibility to breast cancer is highly increased with mutations in breast cancer susceptibility genes (BRCA1 and BRCA2). BRCA mutated breast carcinomas are commonly seen in younger patients and have a more aggressive clinical course.
Wild Type and Mutated BRCA – Differentiation of Breast Cancer using New miRNA Biomarker Panel
Breast cancer represents a heterogeneous group of tumors characterized by a wide range of clinical, pathologic and molecular features. Genetic susceptibility to breast cancer is highly increased with mutations in breast cancer susceptibility genes (BRCA1 and BRCA2).
Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AD) Differentiation in Non-Small Cell Lung Cancer (NSCLC) using New miRNA Biomarker Panel
Lung cancer represents a heterogeneous group of tumors comprised of mostly squamous cell carcinomas (SCC) and adenocarcinomas (AD). These tumors can be challenging to classify due to heterogeneity, sampling and lack of differentiation.
Triple Negative Breast Cancer – Differentiation of TNBC (ER-, PR-, and HER2/neu-) using New miRNA Biomarker Panel
Like many cancers, breast cancers are highly diverse with a range of distinct clinical outcomes. Breast cancers dependent on hormone signaling (estrogen receptor [ER]/ progesterone receptor [PR]) or on epidermal growth factor receptor (HER2/neu) typically have the most positive prognosis.
Prostate Cancer (PC) and Benign Prostatic Hyperplasia (BPH) Differentiation by New miRNA Biomarker Panel
Prostate cancer and benign prostatic hyperplasia (BPH) are the most frequent and deadly pathologies of the prostate gland. It is estimated that in 2018, 164,690 new cases and 29,430 deaths may occur due to prostate cancer in the United States of America.
Sorry, no results were found for your search.
Please try again with different keywords